CFHR4 and neoplasm: We hypothesised that a multimeric recombinant FHR4 molecule, combined to a targeting moiety recognising a tumour‐associated antigen, could selectively accumulate on target tumour cells, enhancing the local stoichiometry of FHR4, thereby allowing the tumour cell‐established complement inhibition threshold (CIT) to be overcome.